scholarly journals Uptake kinetics of the somatostatin receptor ligand [ 86 Y]DOTA- d Phe 1 -Tyr 3 -octreotide ([ 86 Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90 Y-labelled analogue

1999 ◽  
Vol 26 (4) ◽  
pp. 358-366 ◽  
Author(s):  
Frank Rösch ◽  
Hans Herzog ◽  
Barbara Stolz ◽  
Jörg Brockmann ◽  
Martin Köhle ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Somatostatin Receptor ◽  
Uptake Kinetics ◽  
Emission Tomography ◽  
Radiation Doses ◽  
Receptor Ligand ◽  
Positron Emission ◽  
Somatostatin Receptor Ligand ◽  
Kinetics Of

scholarly journals Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Jiale Hou ◽  
Yi Yang ◽  
Na Chen ◽  
Dengming Chen ◽  
Shuo Hu
Keyword(s):  
Positron Emission Tomography ◽  
Neuroendocrine Tumors ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Somatostatin Receptor ◽  
Progression Free Survival ◽  
Emission Tomography ◽  
Cochrane Library ◽  
Positron Emission ◽  
Pet Ct

Purpose: A meta-analysis was conducted to investigate the value of the volume parameters based on somatostatin receptor (SSTR)-positron emission tomography (PET) in predicting the prognosis in patients with neuroendocrine tumors (NETs).Material: PUBMED, EMBASE, Cochrane library, and Web of Knowledge were searched from January 1990 to May 2021 for studies evaluating prognostic value of volume-based parameters of SSTR PET/CT in NETs. The terms used were “volume,” “positron emission tomography,” “neuroendocrine tumors,” and “somatostatin receptor.” Pooled hazard ratio (HR) values were calculated to assess the correlations between volumetric parameters, including total tumor volume (TTV) and total-lesion SSTR expression (TL-SSTR), with progression-free survival (PFS) and overall survival (OS). Heterogeneity and subgroup analysis were performed. Funnel plots, Begg's and Egger's test were used to assess possible underlying publication bias.Results: Eight eligible studies involving 593 patients were included in the meta-analysis. In TTV, the pooled HRs of its prognostic value of PFS and OS were 2.24 (95% CI: 1.73–2.89; P < 0.00001) and 3.54 (95% CI, 1.77–7.09; P = 0.0004), respectively. In TL-SSTR, the pooled HR of the predictive value was 1.61 (95% CI, 0.48–5.44, P = 0.44) for PFS.Conclusion: High TTV was associated with a worse prognosis for PFS and OS in with patients NETs. The TTV of SSTR PET is a potential objective prognosis predictor.

Abstract 460: 64 Cu-DOTATATE for in vivo Positron Emission Tomography Imaging of Somatostatin Receptor 2 Expressing Macrophages in a Göttingen Minipig Model of Atherosclerosis

2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Sune Folke Pedersen ◽  
Trine Pagh Ludvigsen ◽  
Andreas Vegge ◽  
Camilla Schumacher-Petersen ◽  
Rasmus Sejersten Ripa ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Abdominal Aorta ◽  
Right Atrium ◽  
Plasma Lipids ◽  
Somatostatin Receptor ◽  
Emission Tomography ◽  
Activated Macrophages ◽  
Lean Control ◽  
Positron Emission

Background: Somatostatin receptor subtype 2 (SSTR 2 ) is expressed by activated macrophages which are important effector cells in atherogenesis and a major constituent of atherosclerotic plaques. SSTR 2 can be targeted non-invasively in vivo using the tracer 64 Cu-DOTATATE and positron emission tomography (PET). Methods: Male castrated Göttingen minipigs were treated according to two diet regimes for 43 weeks: chow (lean control; n=1) or high-fat/high-cholesterol diet (HFHC, obese group; n=2). Plasma lipids: total cholesterol (TC) and triglycerides (TG) were measured and SSTR 2 expression was assessed using hybrid positron emission tomography/magnetic resonance (PET/MR) imaging of the abdominal aorta, one hour (range: 60-63 minutes) post injection with 200 MBq (range 202-214 MBq) of 64 Cu-DOTATATE. Consectutive regions of interest (ROIs) were drawn guided by MR to include vessel wall and lumen of the abdominal aorta to calculate standardized uptake values (SUVs). Target-to-background (TBR) ratios were calculated using right atrium SUVs for blood pool correction (SUV vessel /SUV right atrium = TBR) and reported as mean and maximal values (TBR mean ; TBR max ). Results: Three minipigs (age 17 months) were included and PET/MR was completed in all animals. Mean uptake of 64 Cu-DOTATATE was lowest for the abdominal aorta in the lean control: TBR mean = 0.44 and TBR max = 0.73 (range: TBR mean = 0.29 - 0.62; TBR max = 0.49 - 1.10) and highest in the HFHC group: TBR mean = 0.66 and TBR max = 1.28 (range: TBR mean = 0.26 - 1.38; TBR max = 0.39 - 3.19). Plasma lipids: lean control: TC = 1.34 mmol/L; TG = 0.38 mmol/L; HFHC group (mean values): TC = 18.7mmol/L (range: 11.6 - 25.8mmol/L); TG = 0.6 mmol/L (range: 0.37 - 0.83mmol/L). Conclusion: Non-invasive 64 Cu-DOTATATE PET/MR is feasible for assessment of SSTR 2 expression in a Göttingen minipig model of diet-induced atherosclerosis. Additional studies are needed including assessment of histology findings and gene expression to confirm the presence of activated macrophages in order to validate the use of 64 Cu-DOTATATE PET/MR in this model.

scholarly journals Noninvasive and Quantitative Monitoring of the Distributions and Kinetics of MicroRNA-Targeting Molecules in Vivo by Positron Emission Tomography

2019 ◽  
Vol 16 (4) ◽  
pp. 1507-1515 ◽  
Author(s):  
Jussi Mäkilä ◽  
Anu Kiviniemi ◽  
Tiina Saanijoki ◽  
Heidi Liljenbäck ◽  
Meeri Käkelä ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Positron Emission ◽  
Quantitative Monitoring ◽  
Kinetics Of

A Double-Injection Technique for in vivo Measurement of Dopamine D2-Receptor Density in Monkeys with 3-(2'-[18F] Fluoroethyl)Spiperone and Dynamic Positron Emission Tomography

1989 ◽  
Vol 9 (6) ◽  
pp. 850-858 ◽  
Author(s):  
Sung-Cheng Huang ◽  
Mark M. Bahn ◽  
Jorge R. Barrio ◽  
John M. Hoffman ◽  
Nagichettiar Satyamurthy ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Receptor Binding ◽  
Dopamine D2 Receptor ◽  
D2 Receptor ◽  
Emission Tomography ◽  
Injection Technique ◽  
Receptor Density ◽  
Dopamine D2 ◽  
Positron Emission ◽  
Kinetics Of

Dopamine D2-receptor density in striatum of monkey was measured with 3-(2'-[18F]fluoroethyl)spiperone (FESP) and dynamic positron emission tomography (PET), using a double-injection technique. A first bolus of high specific activity (SA) FESP (5 mCi; ≃ 1 Ci/μmol) was injected i.v.; 90 min later, a second bolus of lower SA FESP (5 mCi; ≃ 0.04 Ci/μmol) was injected. A dynamic PET study was performed to measure the kinetics of FESP in striatum over 180 min, and the metabolite-corrected concentration of FESP in plasma as a function of time was obtained from arterial blood samples. A nonlinear compartmental model that took into account the saturability of the receptor binding was used to describe the kinetics of FESP in striatum. Model parameters were estimated by regression with a constraint based on information about the equilibrium dissociation constant of the ligand–receptor binding. Dopamine D2-receptor density in striatum was estimated to be 25.9 ± 12.7 pmol/g in seven Macaca nemestrina monkeys. The method does not require the use of cerebellum as a reference tissue region and an estimate of dopamine D2-receptor density can be obtained from a single study.

scholarly journals [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging

2020 ◽  
Vol 13 (3) ◽  
pp. 38 ◽  
Author(s):  
Ute Hennrich ◽  
Martina Benešová
Keyword(s):  
United States ◽  
Positron Emission Tomography ◽  
Somatostatin Receptor ◽  
The United States ◽  
Emission Tomography ◽  
Somatostatin Analogue ◽  
Therapy Planning ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Positron Emission ◽  
Disseminated Disease

In the United States, [68Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [68Ga]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide 68Ga with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response.

Kinetics of 11C-Labeled Opiates Studied with Positron Emission Tomography in the Brain of the Rhesus Monkey

1985 ◽  
pp. 97-100
Author(s):  
P. O. Lundberg ◽  
P. Hartvig ◽  
K. Bergström ◽  
B. Lindberg ◽  
H. Lundqvist ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Rhesus Monkey ◽  
Emission Tomography ◽  
Positron Emission ◽  
Kinetics Of ◽  
The Brain

scholarly journals Positron Emission Tomography Study of Brain Benzodiazepine Receptors in Friedreich's Ataxia

1990 ◽  
Vol 17 (4) ◽  
pp. 404-409 ◽  
Author(s):  
C. Chavoix ◽  
Y. Samson ◽  
S. Pappata ◽  
C. Prenant ◽  
M. Mazière ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Benzodiazepine Receptors ◽  
Friedreich’S Ataxia ◽  
Friedreich's Ataxia ◽  
Emission Tomography ◽  
Tracer Injection ◽  
Central Type ◽  
Positron Emission ◽  
Specific Antagonist ◽  
Kinetics Of

ABSTRACT:Central type benzodiazepine receptors were studied in 9 patients with Friedreich's ataxia and 12 healthy subjects using positron emission tomography (PET) and [11C]Ro 15-1788, a specific antagonist of the central type benzodiazepine receptors, as radioligand. A standard PET procedure was used in 5 patients and 8 controls to obtain brain kinetics of the total binding of the radioligand. The remaining subjects were intravenously injected with a saturating dose of unlabeled Ro 15-1788, 30 minutes after the tracer injection, to determine the nondisplaceable binding of [11C]Ro 15-1788. A semi-quantitative method was used to quantify the [11C]Ro 15-1788 data. None of the quantification indices in the cerebellar hemispheres, or in the other brain areas investigated, was significantly modified in patients with Friedreich's ataxia. These findings suggest that brain benzodiazepine receptors are unaffected in Friedreich's ataxia.

Sign in / Sign up

Export Citation Format

Share Document